Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7,325 JPY | +0.80% | +1.31% | +7.69% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's enterprise value to sales, at 3.56 times its current sales, is high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.69% | 13.31B | A- | ||
+25.46% | 659B | C+ | ||
+25.38% | 557B | B | ||
-4.86% | 359B | C+ | ||
+16.44% | 322B | B- | ||
+8.34% | 297B | C+ | ||
+6.13% | 215B | B+ | ||
+2.93% | 210B | B- | ||
-7.65% | 200B | A+ | ||
-8.79% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4507 Stock
- Ratings Shionogi & Co., Ltd.